Please use this identifier to cite or link to this item:
|Title:||Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.|
|Authors:||Campbell, Robert;Chong, Geoffrey;Hawkes, Eliza A|
|Affiliation:||Department of Medical Oncology and Clinical Haematology, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia|
Bendigo Cancer Centre, Bendigo Health, Bendigo, VIC 3084, Australia
Department of Oncology, Northern Hospital, Melbourne, VIC 3084, Australia
Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC 3084, Australia
Department of Medical Oncology, Eastern Health, Melbourne, VIC 3084, Australia
Eastern Health, Monash University Clinical School, Melbourne, VIC 3084, Australia
|Citation:||Journal of clinical medicine 2018; 7(4): 62|
|Abstract:||Bruton's tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the first-in-class agent. A few other BTK inhibitors (BTKi) are also under development (e.g., acalabrutinib). While the predominant action of BTKi is the blockade of B-cell receptor pathway within malignant B-cells, increasing the knowledge of off-target effects as well as a potential role for B-cells in proliferation of solid malignancies is expanding the indication of BTKi into non-hematological malignancies. In addition to the expansion of the role of BTKi monotherapy, combination therapy strategies utilizing ibrutinib with established regimens and combination with modern immunotherapy compounds are being explored.|
|Subjects:||Bruton’s tyrosine kinase|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.